Adenovirus infection features and management
Reading Document
Medical Text Search
adenovirus infection clinical features presentation diagnosis
Medical Text Search
adenovirus management treatment antiviral immunocompromised
GradeResponse
GradeResponse
Here is a comprehensive overview of adenovirus infection:
Adenovirus Infection
Overview
Adenoviruses are non-enveloped double-stranded DNA viruses. There are >50 serotypes in humans, and the clinical syndrome largely depends on the serotype and the host's immune status.
Clinical Features
Immunocompetent Hosts
Most infections are mild and self-limiting. Common presentations include:
| Syndrome | Details |
|---|---|
| Upper respiratory tract infection | Pharyngitis, tonsillitis, rhinitis, coryza — often indistinguishable from other viral URTIs |
| Pharyngoconjunctival fever | Pharyngitis + conjunctivitis + fever; serotypes 3, 7 |
| Epidemic keratoconjunctivitis | Keratitis + follicular conjunctivitis; serotypes 8, 19, 37 — highly contagious |
| Pneumonia | Usually in children and military recruits; serotypes 4, 7; can be severe |
| Gastroenteritis | Watery diarrhea, especially in children; serotypes 40, 41 (enteric adenoviruses) |
| Hemorrhagic cystitis | Gross hematuria, dysuria; serotypes 11, 21 |
| Febrile illness in children | Non-specific fever, may trigger wheezing/exacerbation in asthmatic children |
Immunocompromised Hosts
Adenovirus can cause severe or disseminated disease (Guide to Utilization of the Microbiology Laboratory, p. 106):
- Pneumonia (can be fatal)
- Hepatitis (especially post-transplant)
- Hemorrhagic cystitis (HSCT recipients)
- Meningoencephalitis
- Gastroenteritis / colitis
- Disseminated multiorgan infection
High-risk groups: hematopoietic stem cell transplant (HSCT) recipients, solid organ transplant patients, patients with HIV/AIDS, children with combined immunodeficiencies.
Diagnosis
(Guide to Utilization of the Microbiology Laboratory, p. 106)
| Method | Notes |
|---|---|
| NAAT (PCR) | Preferred; high sensitivity and specificity; available on multiplex respiratory panels (FDA-cleared) |
| Quantitative PCR (plasma viral load) | Useful for preemptive therapy in immunocompromised, monitoring treatment response |
| Viral culture | Turnaround 5–7 days; can be expedited with shell vial technology; lower sensitivity |
| Histopathology | "Smudge cells" (basophilic intranuclear inclusions) on biopsy; useful in tissue-invasive disease |
| Antigen detection / DFA | Rapid, but less sensitive than PCR |
| Serology | Limited clinical utility; used mainly in epidemiologic studies |
Key point: Adenovirus is included in FDA-cleared multiplex respiratory panels, making rapid diagnosis feasible in respiratory illness. Plasma quantitative PCR is the cornerstone for monitoring immunocompromised patients.
Management
Immunocompetent Patients
- Supportive care is the mainstay: hydration, antipyretics, symptomatic relief
- No antiviral treatment is routinely indicated
- Conjunctivitis: topical lubricants; avoid topical steroids (can worsen keratoconjunctivitis)
- Hospitalization for severe pneumonia as clinically warranted
Immunocompromised Patients
Antiviral therapy is considered in severe or disseminated disease, though no FDA-approved antiviral exists specifically for adenovirus:
| Agent | Details |
|---|---|
| Cidofovir | Most commonly used; active against adenovirus in vitro and in clinical use; nephrotoxic — must co-administer probenecid and IV hydration; dose reduced/adjusted in renal impairment |
| Brincidofovir (CMX001) | Lipid-conjugated prodrug of cidofovir; oral, better bioavailability, less nephrotoxicity; showed promise in HSCT but FDA approval status for adenovirus remains investigational in most centers |
| Ribavirin | Limited and inconsistent data; occasionally used as adjunct or when cidofovir is not tolerated |
| IVIG / adenovirus-specific immunoglobulin | Adjunctive in severe immunocompromised cases |
| Reduction of immunosuppression | Critical first step in transplant patients if clinically feasible |
Monitoring in Immunocompromised
- Preemptive therapy: regular plasma quantitative PCR surveillance in high-risk HSCT patients; initiate treatment at rising viral loads before overt disease develops
- Response to therapy is monitored by serial plasma viral load measurements
Prevention
- Hand hygiene and contact precautions (fomite transmission is significant)
- Live oral vaccines (serotypes 4 and 7): licensed and used in U.S. military recruits, not available for civilian use
- Droplet and contact precautions in healthcare settings for epidemic keratoconjunctivitis
- Instrument disinfection in ophthalmology clinics (adenovirus is resistant to many common disinfectants; alcohol-based agents have limited efficacy — use sodium hypochlorite or povidone-iodine)
Key Pearls
- Always consider adenovirus in febrile illness post-HSCT — rising plasma PCR warrants preemptive antiviral therapy
- "Smudge cells" on histopathology are classic but not pathognomonic
- Serotype matters: type 7 causes severe pediatric pneumonia; types 40/41 cause enteric disease; types 8/19/37 cause epidemic keratoconjunctivitis
- Adenovirus can persist latently in tonsillar/adenoid tissue and reactivate under immunosuppression
What are the Hb type levels in different thalassemia types
Medical Text Search
hemoglobin electrophoresis levels HbA HbA2 HbF thalassemia types alpha beta
Medical Text Search
thalassemia classification alpha beta major minor trait hemoglobin pattern
GradeResponse
GradeResponse
Medical Text Search
beta thalassemia major intermedia minor HbA2 HbF percentage hemoglobin electrophoresis findings
Medical Text Search
alpha thalassemia silent carrier trait HbH Bart hydrops fetalis hemoglobin levels
Here is a comprehensive breakdown of hemoglobin (Hb) type levels across the different thalassemia types:
Hemoglobin Types in Thalassemia
Normal Adult Hemoglobin Reference Values
| Hb Type | Composition | Normal Adult Level |
|---|---|---|
| HbA | α₂β₂ | >95% |
| HbA2 | α₂δ₂ | 1.5–3.5% |
| HbF | α₂γ₂ | <1% |
| HbH | β₄ | Absent |
| Hb Bart's | γ₄ | Absent |
(Harrison's, p. 2906)
Beta (β) Thalassemia
In β-thalassemia, reduced/absent β-globin leads to compensatory increases in HbA2 and HbF (δ and γ chains are upregulated to substitute for β chains).
| Condition | Genotype | HbA | HbA2 | HbF | HbH / Hb Bart's |
|---|---|---|---|---|---|
| Silent carrier | β/β (one mild mutation) | Normal (~97%) | Normal or borderline (~3.5%) | Normal (<1%) | Absent |
| β-Thalassemia Trait (Minor) | β⁺/β or β⁰/β | Reduced (~80–90%) | Raised (>3.5%, typically 4–6%) | Mildly raised (1–5%) | Absent |
| β-Thalassemia Intermedia | β⁺/β⁺ or β⁰/β⁺ | Significantly reduced | Raised (>3.5%) | Markedly raised (10–50%) | Absent |
| β-Thalassemia Major (Cooley's anemia) | β⁰/β⁰ or β⁰/β⁺ (severe) | Absent or trace (<10%) | Raised (>3.5%) | Markedly raised (up to 90–98%) | Absent |
Key rule: In all β-thalassemia states (except silent carrier), HbA2 >3.5% is the hallmark diagnostic finding.
Alpha (α) Thalassemia
In α-thalassemia, reduced/absent α-globin leads to excess β chains (forming HbH = β₄) or excess γ chains in neonates (forming Hb Bart's = γ₄). The severity scales with the number of α-globin genes deleted (normally 4 genes: αα/αα).
| Condition | Genes Deleted | HbA | HbA2 | HbF | HbH (β₄) | Hb Bart's (γ₄) |
|---|---|---|---|---|---|---|
| Silent carrier | 1 gene deleted (-α/αα) | Normal (~98%) | Normal or low-normal (<3.5%) | Normal | Absent | Absent (trace at birth) |
| α-Thalassemia Trait (Minor) | 2 genes deleted (-α/-α or --/αα) | Mildly reduced | Normal or low (<3.5%) | Normal | Absent or trace | 1–2% at birth |
| HbH Disease | 3 genes deleted (--/-α) | Reduced | Low | Low | 5–30% (HbH = β₄) | Present at birth (~20–40%), decreases after |
| Hb Bart's Hydrops Fetalis | 4 genes deleted (--/--) | Absent | Absent | Absent | Trace | >80% Hb Bart's (γ₄); incompatible with life |
Key rule: In α-thalassemia, HbA2 is not elevated (unlike β-thalassemia) — this is a critical diagnostic distinction. Diagnosis relies on molecular/genetic testing or detection of HbH on electrophoresis.
Delta-Beta (δβ) Thalassemia & HPFH
| Condition | HbA | HbA2 | HbF |
|---|---|---|---|
| δβ-Thalassemia trait | Reduced | Normal or low (<3.5%) | Raised (5–20%) |
| Hereditary Persistence of Fetal Hemoglobin (HPFH) — heterozygous | Mildly reduced | Normal | Raised (15–35%) |
| HPFH — homozygous | Absent | Absent | 100% HbF |
δβ-thalassemia and HPFH both elevate HbF but with normal or low HbA2 — distinguishing them from β-thalassemia trait.
Diagnostic Summary Table
| Finding | Suggests |
|---|---|
| HbA2 >3.5% + mild anemia, microcytosis | β-Thalassemia trait |
| HbA2 >3.5% + HbF >50% + severe anemia | β-Thalassemia major/intermedia |
| HbA2 normal/low + microcytosis + no HbA2 rise | α-Thalassemia (genetic testing needed) |
| HbH band on electrophoresis | HbH disease (3-gene α deletion) |
| >80% Hb Bart's at birth + hydrops | 4-gene α deletion |
| HbF 15–35% + low HbA2 | HPFH |
| HbF 5–20% + low HbA2 + microcytosis | δβ-Thalassemia trait |
Key Pearls
- HbA2 elevation (>3.5%) is the single most reliable screening marker for β-thalassemia trait — iron deficiency can falsely lower HbA2, so iron status must be assessed concurrently.
- α-Thalassemia does NOT raise HbA2 — a common exam and clinical pitfall; HPLC/electrophoresis may appear near-normal, requiring DNA analysis.
- Hb Bart's (γ₄) is detectable on neonatal heel-prick screens and is the primary way silent and trait α-thalassemia are now detected early.
- In compound heterozygosity (e.g., HbS/β-thalassemia), sickle cell disease phenotypes emerge alongside thalassemia patterns.
What is the management for foreign body inhalation with complete obstruction
Medical Text Search
foreign body airway obstruction complete management emergency adults children
Medical Text Search
choking Heimlich maneuver back blows chest thrusts complete airway obstruction
GradeResponse
GradeResponse
Foreign Body Inhalation — Complete Airway Obstruction Management
Complete (severe) airway obstruction is a life-threatening emergency requiring immediate action. The approach is age-dependent.
Recognition of Complete Obstruction
| Feature | Incomplete Obstruction | Complete Obstruction |
|---|---|---|
| Cough | Forceful, effective | Absent or ineffective, silent |
| Speech/cry | Possible | Unable to speak/cry |
| Breathing | Some air movement | None or gasping |
| Skin color | Normal | Cyanosis developing |
| Consciousness | Alert | Deteriorating rapidly |
A patient who cannot cough, speak, or breathe has complete obstruction — act immediately.
Management by Age Group
Adults & Children >1 Year (Conscious)
Step 1 — Encourage coughing
- If any cough is present and effective, encourage continued forceful coughing — do not intervene yet.
Step 2 — 5 Back Blows
- Lean patient forward
- Deliver 5 sharp blows between the shoulder blades with the heel of the hand
- Check after each blow — stop if obstruction relieved
Step 3 — 5 Abdominal Thrusts (Heimlich Maneuver)
(Bailey & Love, p. 283)
- Stand behind patient, one foot forward for stability
- Place one fist (thumb side in) just above the umbilicus and below the xiphisternum
- Grasp fist with other hand
- Give 5 sharp inward and upward thrusts
- Alternate: 5 back blows → 5 abdominal thrusts → repeat cycle
If patient becomes unconscious → start CPR immediately (chest compressions may dislodge the object; look in mouth before each ventilation attempt)
Infants (<1 Year) (Conscious)
(Bailey & Love, p. 283)
Abdominal thrusts are contraindicated in infants due to risk of abdominal organ injury.
Step 1 — 5 Back Blows
- Hold infant face-down, head-down along your forearm
- Support the head
- Deliver 5 firm back blows between shoulder blades with heel of hand
Step 2 — 5 Chest Thrusts (NOT abdominal thrusts)
-
Turn infant face-up, head-down on your thigh
-
Two fingers on lower sternum (one finger-breadth below nipple line)
-
5 sharp downward chest thrusts
-
Alternate cycles and check mouth each time
-
If unconscious → start infant CPR
Pregnant Women & Obese Patients
- Abdominal thrusts are replaced by chest thrusts
- Same position as Heimlich but hands positioned on the lower sternum
In-Hospital / Advanced Management
If basic maneuvers fail or patient is unconscious/arrested:
| Step | Action |
|---|---|
| Direct laryngoscopy | Visualize and attempt removal with Magill forceps if object is in larynx/pharynx |
| Bag-mask ventilation | Attempt oxygenation between removal attempts |
| Rigid bronchoscopy | Definitive method for subglottic/bronchial foreign bodies (Bailey & Love, p. 283, 1005) |
| Surgical airway | Cricothyrotomy or emergency tracheostomy if all else fails and patient cannot be oxygenated |
| CPR | If pulseless — chest compressions may dislodge FB; check oropharynx before each breath |
Post-Removal / Subacute Management
For foreign bodies that have passed beyond the larynx into the bronchial tree (Bailey & Love, p. 1005):
- Right main bronchus (RMB) is the most common site (wider caliber, more vertical)
- Presentations: asymptomatic, unilateral wheeze/obstructive emphysema, or pulmonary suppuration/pneumonia
- Rigid bronchoscopy with a ventilating bronchoscope is the preferred removal technique
- Flexible bronchoscopy used for more distal or peripheral objects
- Chest X-ray (expiratory film): hyperinflated lung, mediastinal shift away from the obstructed side
- If delayed presentation: treat concurrent infection before/during bronchoscopy
Key Pearls
- Do not perform blind finger sweeps — this can push the object deeper
- In infants, always use back blows + chest thrusts (never abdominal thrusts)
- The Heimlich maneuver should not be used in infants or late pregnancy
- Any witnessed choking episode in a child, even if "resolved," warrants bronchoscopic evaluation — objects can lodge silently in the bronchus
- Inspiratory stridor = laryngeal/tracheal obstruction; expiratory wheeze = bronchial obstruction
- RMB involvement is more common due to its anatomy (more vertical, wider)
This is a shared conversation. Sign in to Orris to start your own chat.